Van Hulzen Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Van Hulzen Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,683	Closed	-$218K	–	234
2018 Q2	$218K	Buy	+1,683	New	+$188K	0.06%	175
2017 Q3	–	Sell	-2,749	Closed	-$208K	–	186
2017 Q2	$208K	Buy	+2,749	New	+$192K	0.08%	129
2016 Q4	–	Sell	-1,771	Closed	-$113K	–	152
2016 Q3	$113K	Buy	+1,771	New	+$130K	0.06%	143

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Van Hulzen Asset Management's LGND Position: Q3 2018 in Review

Van Hulzen Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2018, closing a stake of 1,683 shares — an estimated $218K sold.

Van Hulzen Asset Management first reported a position in LGND in Q3 2016 and held it in 3 quarters. The position peaked at $218K in Q2 2018. 385 funds tracked by Wall St. Rank hold LGND as of Q3 2018.

Van Hulzen Asset Management reported no remaining Ligand Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Van Hulzen Asset Management sold 1,683 Ligand Pharmaceuticals shares in Q3 2018, an estimated $218K.
Van Hulzen Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2016 and held it in 3 quarters.
Van Hulzen Asset Management's Ligand Pharmaceuticals position peaked at $218K in Q2 2018.
385 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2018.

Based on Van Hulzen Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.